Albuterol inhaler ( DrugBank: Albuterol )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 89 | Lymphangioleiomyomatosis | 1 |
89. Lymphangioleiomyomatosis
Clinical trials : 39 / Drugs : 46 - (DrugBank : 20) / Drug target genes : 27 - Drug target pathways : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01799538 (ClinicalTrials.gov) | June 10, 2013 | 23/2/2013 | Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis | Bronchodilator Effects of Nebulized Versus Inhaled Albuterol in Subjects With Lymphangioleiomyomatosis | Lymphangioleiomyomatosis | Drug: albuterol inhaler;Drug: albuterol nebulizer;Procedure: PFT | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Recruiting | 18 Years | N/A | Female | 100 | Phase 1/Phase 2 | United States |